Urogen Pharma Ltd at H.C. Wainwright BioConnect Investor Conference Transcript
Thank you very much for joining us in this next -- in our series of fireside chats this morning here at the H.C. Wainwright BioConnect conference. For those who don't know me, my name is Raghuram Selvaraju. I'm Managing Director and senior healthcare equity research analyst here at H.C. Wainwright in the equity research department.
I'm joined here by CEO Liz Barrett of UroGen Pharma, traded on the Nasdaq under the ticker symbol, URGN. And H.C. Wainwright covers UroGen, with a buy rating and 12-month price target of $23 per share.
Liz, it's a pleasure to have you with us.
Thank you. Thank you for having us.
Questions & Answers
So for those who don't know, UroGen is a commercial-stage company with a product on the market called JELMYTO, which is used for treatment of upper tract urothelial carcinoma. Liz, perhaps you could give us a sense of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
